Teva Reports New Data on Ecopipam for Pediatric Tourette Syndrome

Teva Pharmaceuticals announced new efficacy and safety data for ecopipam, an investigational treatment targeting pediatric patients with Tourette Syndrome. Ecopipam is a first-in-class selective D1 dopamine receptor antagonist.